Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Rapid increase in breast magnetic resonance imaging use: trends from 2000 to 2011.

Stout NK, Nekhlyudov L, Li L, Malin ES, Ross-Degnan D, Buist DS, Rosenberg MA, Alfisher M, Fletcher SW.

JAMA Intern Med. 2014 Jan;174(1):114-21. doi: 10.1001/jamainternmed.2013.11958.

2.

Patterns of breast magnetic resonance imaging use in community practice.

Wernli KJ, DeMartini WB, Ichikawa L, Lehman CD, Onega T, Kerlikowske K, Henderson LM, Geller BM, Hofmann M, Yankaskas BC; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2014 Jan;174(1):125-32. doi: 10.1001/jamainternmed.2013.11963.

3.

Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.

Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.

PMID:
23940285
4.

Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination.

Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA.

JAMA. 2004 Sep 15;292(11):1317-25.

PMID:
15367553
5.

Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.

Plevritis SK, Kurian AW, Sigal BM, Daniel BL, Ikeda DM, Stockdale FE, Garber AM.

JAMA. 2006 May 24;295(20):2374-84.

PMID:
16720823
6.

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.

BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.

7.

Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer.

Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, Litton JK, Arun BK.

Cancer. 2011 Sep 1;117(17):3900-7. doi: 10.1002/cncr.25971. Epub 2011 Mar 1.

8.

Evaluation of mammographic surveillance services in women aged 40-49 years with a moderate family history of breast cancer: a single-arm cohort study.

Duffy SW, Mackay J, Thomas S, Anderson E, Chen TH, Ellis I, Evans G, Fielder H, Fox R, Gui G, Macmillan D, Moss S, Rogers C, Sibbering M, Wallis M, Warren R, Watson E, Whynes D, Allgood P, Caunt J.

Health Technol Assess. 2013 Mar;17(11):vii-xiv, 1-95. doi: 10.3310/hta17110.

9.

Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness.

de Bock GH, Vermeulen KM, Jansen L, Oosterwijk JC, Siesling S, Dorrius MD, Feenstra T, Houssami N, Greuter MJ.

Br J Cancer. 2013 Apr 30;108(8):1579-86. doi: 10.1038/bjc.2013.149. Epub 2013 Apr 11.

10.

Early uptake of breast magnetic resonance imaging in a community-based medical practice, 2000-2004.

Stout NK, Nekhlyudov L.

J Womens Health (Larchmt). 2011 Apr;20(4):631-4. doi: 10.1089/jwh.2010.2159. Epub 2011 Mar 17.

11.

The American Cancer Society guidelines for breast screening with magnetic resonance imaging: an argument for genetic testing.

Murphy CD, Lee JM, Drohan B, Euhus DM, Kopans DB, Gadd MA, Rafferty EA, Specht MC, Smith BL, Hughes KS.

Cancer. 2008 Dec 1;113(11):3116-20. doi: 10.1002/cncr.23913.

12.

Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging.

Warner E, Hill K, Causer P, Plewes D, Jong R, Yaffe M, Foulkes WD, Ghadirian P, Lynch H, Couch F, Wong J, Wright F, Sun P, Narod SA.

J Clin Oncol. 2011 May 1;29(13):1664-9. doi: 10.1200/JCO.2009.27.0835. Epub 2011 Mar 28.

13.

Use of breast MRI surveillance in women at high risk for breast cancer: a single-institutional experience.

Elmore L, Margenthaler JA.

Ann Surg Oncol. 2010 Oct;17 Suppl 3:263-7. doi: 10.1245/s10434-010-1236-4. Epub 2010 Sep 19.

PMID:
20853044
14.

Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.

Passaperuma K, Warner E, Causer PA, Hill KA, Messner S, Wong JW, Jong RA, Wright FC, Yaffe MJ, Ramsay EA, Balasingham S, Verity L, Eisen A, Curpen B, Shumak R, Plewes DB, Narod SA.

Br J Cancer. 2012 Jun 26;107(1):24-30. doi: 10.1038/bjc.2012.204. Epub 2012 May 15.

15.

MRI screening in a clinic population with a family history of breast cancer.

Yu J, Park A, Morris E, Liberman L, Borgen PI, King TA.

Ann Surg Oncol. 2008 Feb;15(2):452-61. Epub 2007 Nov 17.

PMID:
18026801
16.

Magnetic resonance imaging improves breast screening sensitivity in BRCA mutation carriers age ≥ 50 years: evidence from an individual patient data meta-analysis.

Phi XA, Houssami N, Obdeijn IM, Warner E, Sardanelli F, Leach MO, Riedl CC, Trop I, Tilanus-Linthorst MM, Mandel R, Santoro F, Kwan-Lim G, Helbich TH, de Koning HJ, Van den Heuvel ER, de Bock GH.

J Clin Oncol. 2015 Feb 1;33(4):349-56. doi: 10.1200/JCO.2014.56.6232. Epub 2014 Dec 22.

PMID:
25534390
17.

Reasons for risk-reducing mastectomy versus MRI-screening in a cohort of women at high hereditary risk of breast cancer.

Haroun I, Graham T, Poll A, Sun P, Hill K, Weitzner E, Narod S, Warner E.

Breast. 2011 Jun;20(3):254-8. doi: 10.1016/j.breast.2011.01.006. Epub 2011 Feb 8.

18.

Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined.

Heijnsdijk EA, Warner E, Gilbert FJ, Tilanus-Linthorst MM, Evans G, Causer PA, Eeles RA, Kaas R, Draisma G, Ramsay EA, Warren RM, Hill KA, Hoogerbrugge N, Wasser MN, Bergers E, Oosterwijk JC, Hooning MJ, Rutgers EJ, Klijn JG, Plewes DB, Leach MO, de Koning HJ.

Cancer Epidemiol Biomarkers Prev. 2012 Sep;21(9):1458-68. doi: 10.1158/1055-9965.EPI-11-1196. Epub 2012 Jun 28.

19.

Utilization of breast cancer screening with magnetic resonance imaging in community practice.

Hill DA, Haas JS, Wellman R, Hubbard RA, Lee CI, Alford-Teaster J, Wernli KJ, Henderson LM, Stout NK, Tosteson ANA, Kerlikowske K, Onega T.

J Gen Intern Med. 2018 Mar;33(3):275-283. doi: 10.1007/s11606-017-4224-6. Epub 2017 Dec 6.

20.

Screening magnetic resonance imaging recommendations and outcomes in patients at high risk for breast cancer.

Ehsani S, Strigel RM, Pettke E, Wilke L, Tevaarwerk AJ, DeMartini WB, Wisinski KB.

Breast J. 2015 May-Jun;21(3):246-53. doi: 10.1111/tbj.12396. Epub 2015 Mar 17.

Supplemental Content

Support Center